Two antibodies discovered in the fight against Alzheimer’s
Scientists developing treatments for the devastating brain disorder Creutzfeldt-Jakob Disease (CJD) have unexpectedly blocked the onset of Alzheimer's disease, the most common cause of dementia through the use of two antibodies. These two antibodies, ICSM 18 and 35,...
New Alzheimer research
A fascinating experiment has Alzheimer Research heading off in a new direction. Stuart Feinstein, professor of Molecular, Cellular and Developmental Biology, and co-director of UCSB's Neuroscience Research Institute, and his research team found that when they added...
The Bilingual Advantage
Cognitive neuroscientist, Ellen Bialystok spoke to the New York Times about her 40 years of research into the benefits of bilingualism and its role in delaying the onset of Alzheimer’s disease symptoms. Her conclusion is essentially that through using two languages...
Caring for the caregiver
Dr. Marc E. Agronin, a geriatric psychiatrist and mental health director for the Miami Jewish Health Systems was featured in The New York Times Sunday edition. The focus of the article is on the work he does with caregivers. The highlight of the article are the...
Maria Shriver writes “A Woman’s Nation Takes on Alzheimer’s”
Maria Shriver writes movingly about her experience as a child of Alzheimer’s following the death of her father Sargent Shriver from Alzheimer’s disease, in a report she wrote in partnership with the Alzheimer’s Association. The report included a nationwide survey and...
The U.S. National Institute on Aging/Alzheimer’s Association updates guidelines
The new guidelines released by the National Institute on Aging/Alzheimer’s Association cover three distinct stages of Alzheimer’s disease. The first two stages are mainly useful for research purposes, while the last stage is most relevant for doctors and patients. The...